Dr. Reddy’s Foundation in association with ICRISAT, CIMMYT and CRIDA jointly hosts round table Experts Consultation

Dr. Reddy’s Foundation, International Crop Research Institute for Semi-Arid Tropics (ICRISAT), International Maize and Wheat Improvement Center (CIMMYT) and ICAR-Central Research Institute for Dryland Agriculture (CRIDA) are jointly organizing a consultation of global and local experts on “Regenerative Agriculture for Sustainable Ecosystem and Economy” on 20th September 2022 at ICRISAT, Hyderabad, from 9.00 am onwards.

Dr. Reddy’s Foundation (DRF) was incepted in 1996 by Dr. Kallam Anji Reddy,a renowned scientist,
entrepreneur and philanthropist established and founder of Dr. Reddy’s Laboratories Limited. DRF
aims to innovate for a better and sustainable future and is focused on enhancing the dignity and
well-being of low-income groups.
The purpose of this event is to encourage experts to have an open dialogue where they can share
their learnings and also elaborate on adaptation strategies and explore meaningful collaborations
and partnerships.
Among the topics that will be deliberated on include practices and developing technologies for
regenerative farming (especially for small land holders or marginal farmers), how to scale-up and
address some grass root challenges apart from how to explore the huge scope for carbon marketing
in India which could benefit farmers and developmental organizations if we collaborate and engage
in meaningful partnerships.
Dr. Reddy’s Laboratories Limited is a global pharmaceutical company. With 20 years of leadership in
sustainability, the core value and audacious ESG goals are central to the company’s strategy and
purpose. Following the tenet of its founder Dr. Anji Reddy- ‘Giving back to society’, the company’s
community development programmes target four broad areas: Education, Skilling and Livelihood,
Health and Environmental Sustainability.

This year, DRL refreshed its sustainability and ESG goals
for the next decade. Propelled by bold targets in being committed to environmental stewardship,
its aims to be 100% renewable power (RE100) by 2030, Carbon neutral in direct emissions by 2030,
12.5% reduction in indirect carbon emissions by 2030 and Water-positive by 2025. With affordability and innovation, it aims to triple its existing reach to touch the lives of over 1.5 billion
patients by 2030. It is also equally aggressive on diversity and inclusion, and corporate governance.